The A/G allele of eIF3a rs3740556 predicts platinum-based chemotherapy resistance in lung cancer patients

Lung Cancer

Volumn 79, Issue 1, 2013, Pages 65-72

  Xu, Xiaojing ^a   Han, Lifang ^a   Yang, Huaping ^b   Duan, Li ^c   Zhou, Boting ^b   Zhao, Yingchun ^d   Qu, Jian ^a   Ma, Rui ^e   Zhou, Honghao ^a   Liu, Zhaoqian ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c WUHAN UNIVERSITY   (China)

^d CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

EIF3a; Lung cancer; Platinum chemotherapy; Resistance; Survival analysis

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; EUKARYOTIC TRANSLATION INITIATION FACTOR 3A; GEMCITABINE; INITIATION FACTOR; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CYTOLOGY; EXON; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; INTRON; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CARCINOMA; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; UNDIFFERENTIATED CARCINOMA;

ADENINE; ADULT; ALLELES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE, NEOPLASM; EUKARYOTIC INITIATION FACTOR-3; GENETIC ASSOCIATION STUDIES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PLATINUM COMPOUNDS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84871071642     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.10.005     Document Type: Article

References (30)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics. CA Cancer J Clin 2008, 60(5):277-300.
2. Spira A., Ettinger D.S. Multidisciplinary management of lung cancer. N Engl J Med 2004, 350(4):379-392.
3. Donnelly J.G. Pharmacogenetics in cancer chemotherapy: balancing toxicity and response. Ther Drug Monit 2004, 26(2):231-235.
4. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7(8):573-584.
5. Stordal B., Davey M. Understanding cisplatin resistance using cellular models. IUBMB Life 2007, 59(11):696-699.
6. Chen J., Jiang R., Garces Y.I., Jatoi A., Stoddard S.M., Sun Z., et al. Prognostic factors for limited-stage small cell lung cancer: a study of 284 patients. Lung Cancer 2011, 67(2):221-226.
7. Yamayoshi Y., Iida E., Tanigawara Y. Cancer pharmacogenomics: international trends. Int J Clin Oncol 2005, 10(1):5-13.
8. Deeken J.F., Figg W.D., Bates S.E., Sparreboom A. Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anticancer Drugs 2007, 18(2):111-126.
9. Pestova T.V., Kolupaeva V.G. The roles of individual eukaryotic translation initiation factors in ribosomal scanning and initiation codon selection. Genes Dev 2002, 16(22):2906-2922.
10. Zhou C., Arslan F., Wee S., Krishnan S., Ivanov A.R., Oliva A., et al. PCI proteins eIF3e and eIF3m define distinct translation initiation factor 3 complexes. BMC Biol 2005, 3:p14.
11. Dong Z., Liu L.H., Han B., Pincheira R., Zhang J.T. Role of eIF3 p170 in controlling synthesis of ribonucleotide reductase M2 and cell growth. Oncogene 2004, 23(21):3790-3801.
12. Dellas A., Torhorst J., Bachmann F., Banziger R., Schultheiss E., Burger M.M. Expression of p150 in cervical neoplasia and its potential value in predicting survival. Cancer 1998, 83(7):1376-1383.
13. Haybaeck J., O'Connor T., Spilka R., Spizzo G., Ensinger C., Mikuz G., et al. Overexpression of p150, a part of the large subunit of the eukaryotic translation initiation factor 3, in colon cancer. Anticancer Res 2010, 30(4):1047-1055.
14. Jie S.H.E.N., Hui-hua L.I., Li-hui L.I.U., Yuan-ming T.A.N., Hong-hao Z.H.O.U., Zhao-qian L. Expression of eIF3S10 in lung cancer and its relationship with chemotherapy response. J Int Pathol Clin Med 2006, 26(5):369-371.
15. Rosell R., Taron M., Barnadas A., Scagliotti G., Sarries C., Roig B. Nucleotide excision repair pathways involved in cisplatin resistance in non-small-cell lung cancer. Cancer Control 2003, 10(4):297-305.
16. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998, 24(5):331-344.
17. Fojo T. Cancer DNA repair mechanisms, and resistance to chemotherapy. J Natl Cancer Inst 2001, 93(19):1434-1436.
18. Isla D., Sarries C., Rosell R., Alonso G., Domine M., Taron M., et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004, 15(8):1194-1203.
19. Ryu J.S., Hong Y.C., Han H.S., Lee J.E., Kim S., Park Y.M., et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004, 44(3):311-316.
20. Guertin D.A., Sabatini D.M. An expanding role for mTOR in cancer. Trends Mol Med 2005, 11(8):353-361.
21. Harris T.E., Chi A., Shabanowitz J., Hunt D.F., Rhoads R.E., Lawrence J.C. mTOR-dependent stimulation of the association of eIF4G and eIF3 by insulin. EMBO J 2006, 25(8):1659-1668.
22. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216.
23. Martin L.P., Hamilton T.C., Schilder R.J. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008, 14(5):1291-1295.
24. Weaver D.A., Crawford E.L., Warner K.A., Elkhairi F., Elkhairi F., Khuder S.A., et al. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer 2005, 4(1):18.
25. Wang G., Dombkowski A., Chuang L., Xu X.X. The involvement of XPC protein in the cisplatin DNA damaging treatment-mediated cellular response. Cell Res 2004, 14(4):303-314.
26. Beevers C.S., Li F., Liu L., Huang S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer 2006, 119(4):757-764.
27. Holz M.K., Ballif B.A., Gygi S.P., Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 2005, 123(4):569-580.
28. Haybaeck J., O'Connor T., Spilka R., Spizzo G., Ensinger C., Mikuz G., et al. Overexpression of p150, a part of the large subunit of the eukaryotic translation initiation factor 3, in colon cancer. Anticancer Res 2010, 30(4):1047-1055.
29. Chen G., Burger M.M. p150 expression and its prognostic value in squamous-cell carcinoma of the esophagus. Int J Cancer 1999, 84(2):95-100.
30. Chen G., Burger M.M. p150 overexpression in gastric carcinoma: the association with p53, apoptosis and cell proliferation. Int J Cancer 2004, 112(3):393-398.